These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 37879433)

  • 1. Evaluation of an injectable monthly extended-release buprenorphine program in a low-barrier specialty addiction medicine clinic.
    Heil J; Salzman M; Hunter K; Baston KE; Milburn C; Schmidt R; Haroz R; Ganetsky VS
    J Subst Use Addict Treat; 2024 Jan; 156():209183. PubMed ID: 37879433
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Extended-release pharmacotherapy for opioid use disorder (EXPO): protocol for an open-label randomised controlled trial of the effectiveness and cost-effectiveness of injectable buprenorphine versus sublingual tablet buprenorphine and oral liquid methadone.
    Marsden J; Kelleher M; Hoare Z; Hughes D; Bisla J; Cape A; Cowden F; Day E; Dewhurst J; Evans R; Hearn A; Kelly J; Lowry N; McCusker M; Murphy C; Murray R; Myton T; Quarshie S; Scott G; Turner S; Vanderwaal R; Wareham A; Gilvarry E; Mitcheson L
    Trials; 2022 Aug; 23(1):697. PubMed ID: 35986418
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Retention in care for persons with opioid use disorder transitioning from sublingual to injectable buprenorphine.
    Stein MD; VanNoppen D; Herman DS; Anderson BJ; Conti M; Bailey GL
    J Subst Abuse Treat; 2022 May; 136():108661. PubMed ID: 34801283
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world outcomes with extended-release buprenorphine (XR-BUP) in a low threshold bridge clinic: A retrospective case series.
    Peckham AM; Kehoe LG; Gray JR; Wakeman SE
    J Subst Abuse Treat; 2021 Jul; 126():108316. PubMed ID: 34116808
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial.
    Lee JD; Nunes EV; Novo P; Bachrach K; Bailey GL; Bhatt S; Farkas S; Fishman M; Gauthier P; Hodgkins CC; King J; Lindblad R; Liu D; Matthews AG; May J; Peavy KM; Ross S; Salazar D; Schkolnik P; Shmueli-Blumberg D; Stablein D; Subramaniam G; Rotrosen J
    Lancet; 2018 Jan; 391(10118):309-318. PubMed ID: 29150198
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
    Haight BR; Learned SM; Laffont CM; Fudala PJ; Zhao Y; Garofalo AS; Greenwald MK; Nadipelli VR; Ling W; Heidbreder C;
    Lancet; 2019 Feb; 393(10173):778-790. PubMed ID: 30792007
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hospital-initiated Extended-release Injectable Buprenorphine Using a Novel Reallocation Initiative From an Outpatient Addiction Medicine Clinic.
    Ganetsky VS; Salzman M; Carroll G; Heil J; Sutton J; Visioli VM; Currie S; Schmidt R; Baston KE; Haroz R
    J Addict Med; 2023 Jan-Feb 01; 17(1):108-110. PubMed ID: 36166670
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Buprenorphine Naloxone and Extended Release Injectable Naltrexone for the Treatment of Opioid Use Disorder Among a Veteran Patient Sample: A Retrospective Chart Review.
    Shirk SD; Ameral V; Kraus SW; Houchins J; Kelly M; Pugh K; Reilly E; Desai N
    J Dual Diagn; 2021; 17(3):207-215. PubMed ID: 34176448
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Open-label investigation of rapid initiation of extended-release buprenorphine in patients using fentanyl and fentanyl analogs.
    Mariani JJ; Dobbins RL; Heath A; Gray F; Hassman H
    Am J Addict; 2024 Jan; 33(1):8-14. PubMed ID: 37936553
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population.
    Morgan JR; Schackman BR; Leff JA; Linas BP; Walley AY
    J Subst Abuse Treat; 2018 Feb; 85():90-96. PubMed ID: 28733097
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Examining the benefit of a higher maintenance dose of extended-release buprenorphine in opioid-injecting participants treated for opioid use disorder.
    Greenwald MK; Wiest KL; Haight BR; Laffont CM; Zhao Y
    Harm Reduct J; 2023 Dec; 20(1):173. PubMed ID: 38042801
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extended-release Buprenorphine Administered at Discharge in Hospitalized Persons With Opioid Use Disorder: A Case Series.
    Hansen ER; South AM; Lofwall MR; Fanucchi LC
    J Addict Med; 2024 Jan-Feb 01; 18(1):65-67. PubMed ID: 37874645
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extended-release buprenorphine outcomes among treatment resistant veterans.
    Cotton AJ; Lo K; Kurtz FB; Waldbauer L
    Am J Drug Alcohol Abuse; 2022 May; 48(3):334-337. PubMed ID: 34780319
    [No Abstract]   [Full Text] [Related]  

  • 14. An alternative analysis of illicit opioid use during treatment in a randomized trial of extended-release naltrexone versus buprenorphine-naloxone: A per-protocol and completers analysis.
    Mitchell MM; Schwartz RP; Choo TH; Pavlicova M; O'Grady KE; Gryczynski J; Stitzer ML; Nunes EV; Rotrosen J
    Drug Alcohol Depend; 2021 Feb; 219():108422. PubMed ID: 33352487
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exploring the Interactions between Non-Medical Methamphetamine Use and Prescribed Buprenorphine or Naltrexone in Opioid Use Disorder Treatment Retention.
    Gainer DM; Nahhas RW; Vanderhoof T; Silverstein SM; Wright MD; Vanderhoof SO; Miller SC
    Subst Use Misuse; 2021; 56(14):2160-2170. PubMed ID: 34538204
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The FASTER-BUP Study, Extended-Release Injectable Buprenorphine for the Treatment of Opioid Use Disorder Among Individuals at High Risk of Overdose: Protocol for an Observational Prospective Study.
    Langlois J; Nolan S; Dickhout P; Cui Z; Paterson J; Fairbairn N; Socías ME
    Subst Use Addctn J; 2024 Apr; 45(2):176-180. PubMed ID: 38254287
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative effectiveness of extended release naltrexone and sublingual buprenorphine for treatment of opioid use disorder among Medicaid patients.
    Ross RK; Nunes EV; Olfson M; Shulman M; Krawczyk N; Stuart EA; Rudolph KE
    medRxiv; 2024 Apr; ():. PubMed ID: 38343815
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Buprenorphine Extended-Release Treatment for Opioid Use Disorder in the Postpartum Period.
    Galati BM; Wenzinger M; Rogers CE; Cooke E; Kelly JC
    Obstet Gynecol; 2023 Nov; 142(5):1148-1152. PubMed ID: 37856853
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of long-acting injectable buprenorphine in the correctional setting.
    Martin RA; Berk J; Rich JD; Kang A; Fritsche J; Clarke JG
    J Subst Abuse Treat; 2022 Nov; 142():108851. PubMed ID: 35939914
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Open-label, rapid initiation pilot study for extended-release buprenorphine subcutaneous injection.
    Hassman H; Strafford S; Shinde SN; Heath A; Boyett B; Dobbins RL
    Am J Drug Alcohol Abuse; 2023 Jan; 49(1):43-52. PubMed ID: 36001871
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.